A retrospective study conducted across 33 US hospitals found that emapalumab-containing regimens stabilized key laboratory parameters and resulted in a high 12-month survival probability in patients with rheumatologic disease–associated hemophagocytic lymphohistiocytosis (HLH). The study included 15 patients with a median age of 5 years, primarily with systemic juvenile idiopathic arthritis or adult-onset Still’s disease. Patients received emapalumab for refractory, recurrent, or progressive disease, with good outcomes observed. Emapalumab treatment led to normalization of laboratory parameters and a significant reduction in glucocorticoid dose. The study was published in Arthritis & Rheumatology, with limitations including missing data and a small sample size. The research was supported by Sobi, the company that markets emapalumab.
Source link
Emapalumab Effective in Rheumatologic Disease–Associated HLH
